Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$4.20B	0.43	3.66 million shs	3.84 million shs
ANIP ANI Pharmaceuticals	$66.30 -2.6%	$62.88	$52.50 ▼ $77.00	$1.47B	0.57	319,965 shs	326,192 shs
ANVS Annovis Bio	$2.66 -5.4%	$2.47	$1.11 ▼ $11.69	$54.76M	1.57	383,936 shs	475,137 shs
LNTH Lantheus	$70.18 -4.6%	$78.80	$69.12 ▼ $118.71	$5.09B	0.12	980,999 shs	1.35 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.57%	-4.76%	-6.88%	-17.46%	+32.36%
ANIP ANI Pharmaceuticals	+2.16%	+2.93%	+7.40%	-1.69%	+8.03%
ANVS Annovis Bio	+1.18%	-2.08%	+6.62%	+127.42%	-77.37%
LNTH Lantheus	-1.09%	-12.20%	-5.54%	-27.36%	-39.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8782 of 5 stars	3.7	1.0	0.0	2.9	2.5	3.1
ANIP ANI Pharmaceuticals	3.7695 of 5 stars	2.5	1.0	3.3	2.7	3.3	1.3
ANVS Annovis Bio	1.5825 of 5 stars	3.5	1.0	0.0	0.6	1.7	0.6
LNTH Lantheus	4.6374 of 5 stars	3.4	2.0	4.2	3.4	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
ANIP ANI Pharmaceuticals	3.00	Buy	$78.88	18.97% Upside
ANVS Annovis Bio	3.00	Buy	$18.00	577.20% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	86.95% Upside

Current Analyst Ratings Breakdown

Latest ANIP, ADMA, ANVS, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/10/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$84.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
4/21/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$62.00 ➝ $65.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.37	$0.51 per share	32.50	$1.48 per share	11.30
ANIP ANI Pharmaceuticals	$614.38M	2.34	$7.40 per share	8.96	$19.11 per share	3.47
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
LNTH Lantheus	$1.53B	3.17	$6.76 per share	10.38	$15.65 per share	4.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	19.68	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.75	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	19.94	11.12	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)

Latest ANIP, ADMA, ANVS, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ANVS Annovis Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.49	N/A	N/A	N/A	$187.18 million	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
ANVS Annovis Bio	N/A	10.68	10.68
LNTH Lantheus	0.49	5.74	5.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
ANVS Annovis Bio	15.83%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
ANIP ANI Pharmaceuticals	11.10%
ANVS Annovis Bio	20.80%
LNTH Lantheus	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable

ANIP, ADMA, ANVS, and LNTH Headlines

Recent News About These Companies

William Blair Sticks to Its Hold Rating for Lantheus (LNTH)

July 18 at 4:32 PM | theglobeandmail.com

Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know

July 18 at 4:32 PM | msn.com

Lantheus (LNTH): Buy, Sell, or Hold Post Q1 Earnings?

July 18 at 11:32 AM | msn.com

Hussman Strategic Advisors Inc. Purchases 10,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 18 at 10:39 AM | marketbeat.com

Jackson Creek Investment Advisors LLC Acquires Shares of 16,012 Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 18 at 10:08 AM | marketbeat.com

Segall Bryant & Hamill LLC Buys Shares of 56,942 Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 18 at 6:50 AM | marketbeat.com

Lantheus' (LNTH) Market Perform Rating Reaffirmed at William Blair

July 17 at 11:22 PM | marketbeat.com

Hardy Reed LLC Purchases New Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 17 at 9:34 AM | marketbeat.com

Why Lantheus (LNTH) Stock Is Down Today

July 16 at 6:22 PM | msn.com

Lantheus (NASDAQ:LNTH) Hits New 52-Week Low - Here's Why

July 16 at 10:59 AM | marketbeat.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by New York State Common Retirement Fund

July 16 at 4:33 AM | marketbeat.com

Rice Hall James & Associates LLC Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 14, 2025 | marketbeat.com

Genus Capital Management Inc. Buys Shares of 7,600 Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 12, 2025 | marketbeat.com

3,582 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Concurrent Investment Advisors LLC

July 12, 2025 | marketbeat.com

Correct Capital Wealth Management Invests $644,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 10, 2025 | marketbeat.com

Bridges Investment Management Inc. Increases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 10, 2025 | marketbeat.com

Principal Financial Group Inc. Has $25.23 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 9, 2025 | marketbeat.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Buy" from Analysts

July 8, 2025 | marketbeat.com

1 Safe-and-Steady Stock on Our Watchlist and 2 to Keep Off Your Radar

July 7, 2025 | finance.yahoo.com

New York State Teachers Retirement System Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 5, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, ADMA, ANVS, and LNTH Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$66.30 -1.74 (-2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$66.36 +0.06 (+0.08%)

As of 04:33 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Annovis Bio NYSE:ANVS

$2.66 -0.15 (-5.41%)

Closing price 03:59 PM Eastern

Extended Trading

$2.70 +0.04 (+1.58%)

As of 07:52 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Lantheus NASDAQ:LNTH

$70.18 -3.42 (-4.65%)

Closing price 04:00 PM Eastern

Extended Trading

$70.92 +0.73 (+1.05%)

As of 07:59 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time